The Relationship Between TNF‐α Inhibitor Potency and HBV Reactivation in Patients With Rheumatic Disorders - Kuo, Meng Hsuan; Tseng, Chih‐Wei; Tseng, Kuo‐Chih; Lu, Ming‐Chi; Tung, Chien‐Hsueh; Chen, Nai‐Tzu; Huang, Kuang‐Yung; Lai, Ning‐Sheng (Liver international, 2025)
Keywords: Adult; Aged; Antirheumatic Agents - adverse effects; Antirheumatic Agents - therapeutic use; Antiviral Agents - therapeutic use; Disease prevention; Etanercept; Female; Hazard assessment; HBV reactivation; Hepatitis B; Hepatitis B Antibodies - blood; Hepatitis B surface antigen; Hepatitis B Surface Antigens - blood; Hepatitis B virus - drug effects; Hepatitis B virus - physiology; Humans; Inhibitors; Male; Middle Aged; Monoclonal antibodies; Prophylaxis; Proportional Hazards Models; Retrospective Studies; Rheumatic diseases; Rheumatic Diseases - drug therapy; rheumatologic patients; Risk Factors; Statistical models; TNF‐α inhibitor potency; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha - antagonists & inhibitors; Virus Activation - drug effects; rheumatologic patients; HBV reactivation; TNF‐α inhibitor potency